Bellerophon Therapeutics Inc. (NASDAQ:BLPH) traded up 6.8% during trading on Thursday . The stock traded as high as $2.10 and last traded at $2.03, with a volume of 442,134 shares traded. The stock had previously closed at $1.90.

Several equities research analysts have commented on the stock. Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Cowen and Company assumed coverage on shares of Bellerophon Therapeutics in a research report on Thursday, March 24th. They set a “buy” rating and a $12.00 target price on the stock.

The company has a 50 day moving average of $1.83 and a 200-day moving average of $2.11. The firm’s market cap is $26.55 million.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.11. Equities research analysts anticipate that Bellerophon Therapeutics Inc. will post ($1.84) earnings per share for the current fiscal year.

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.